CDMO company Laviana Pharma completed Series C+ financing of hundreds of millions of RMB recently. This round of financing, exclusively invested by Lujiang City Construction Investment, is mainly used for the construction of the new drug & API production and R&D industrial park in Lujiang County, Hefei City, China.

Picture shows the aerial view of the new drug & API production and R&D industrial park project

It is reported that the project is located in Longqiao Chemical Park of Anhui Lujiang Hi-Tech Industrial Development Zone, covering a total area of 400 mu (~266,666.68 m2) in Phase I and Phase II. Once the project is completed, it will further enhance Laviana Pharma's R&D and production capacity and comprehensive service capacity for innovative drugs at home and abroad. Laviana Pharma will participate in a wider range of global drug R&D and production customization services to build an innovative pharmaceutical service industry with international influence, and also contribute to the accelerated development of biomedical industry in Hefei at the same time.

Picture shows the signing ceremony of the project, attended by Yu Aihua, member of the Standing Committee of Anhui Provincial Party Committee and Secretary of Hefei Municipal Party Committee and other leaders

Founded in 2003 and headquartered in Jiangsu, Laviana Pharma specializes in industrialization outsourcing services for the innovative pharmaceutical industry, focusing on small molecule innovative drugs, covering the process transformation of innovative pharmaceuticals from laboratory to industrialization, including pre-clinical to post-approval process development, process optimization, pilot and large-scale production. In 2015, the company completed the shareholding system reformation and has laid out R&D centers and production bases in many places at home and abroad, and overseas business centers in Europe, the United States, Japan, etc.

Currently, Laviana Pharma serves more than 100 project orders annually, covering multiple areas such as oncology, central nervous system and metabolic system. Laviana Pharma has established long-term strategic partnerships with many well-known global innovative drug customers.

CDMO is a highly market-oriented and fully competitive industry. The companies worldwide are mainly concentrated in Europe, America and Asia, with CDMO companies in the Asian market mainly located in China and India. China has increasingly become a preferred strategic outsourcing destination for multinational pharmaceutical companies due to its competitive advantages in terms of talent, infrastructure and cost structure. China's pharmaceutical CDMO market has maintained a growth rate of over 20% in recent years, which provides a broad space for Laviana Pharma's rapid growth.

Mr. Chen Wenting, Founder and Chairman and of Laviana Pharma, said that as the trend of globalization of pharmaceutical R&D advances, the horizontal development of multinational pharmaceutical companies - transforming from pharmaceutical companies to therapeutic companies and further to health management companies - will raise their expectation on capacity and technology from outsourcing companies; with the advancement of precision medicine, the requirements for pharmaceutical development and manufacturing are becoming increasingly stringent; as well as the change of human disease spectrum, the division of labor of CDMO will become more and more detailed and standardized in the future, which is undoubtedly a promising development opportunity for Laviana Pharma. Following the corporate mission of "changing the world with art of chemistry", Laviana Pharma will seize development opportunities and accelerate the global pharmaceutical innovation with the dual help of industry dividend and policy support.